Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2017

01-12-2017 | Editorial

Modulation of Gut Microbiota by Maillard Reaction Products in Intestinal Inflammation: Are We What We Eat?

Author: Adam Fabisiak

Published in: Digestive Diseases and Sciences | Issue 12/2017

Login to get access

Excerpt

Although “We are what we eat” is a popular phrase implying that eating certain foods affects one’s health, the phrase is currently gaining scientific credence due to the discovery of the linkage between diet, the intestinal microbiome, and many diseases. Disease entities not only limited to the gastrointestinal (GI) tract are described as microbiota-dependent. As an example, inflammatory bowel disease (IBD) possesses an established etiopathogenesis which comprises the genetic susceptibility and environmental factors associated with changes in the intestinal microbiota. The increasing incidence of IBD correlates with overall global industrialization, which in turn correlates with the “Western pattern diet” [1]. …
Literature
2.
go back to reference ALJahdali N, Gadonna-Widehem P, Delayre-Orthez C, et al. Repeated oral exposure to N ε-carboxymethyllysine, a Maillard reaction product, alleviates gut microbiota dysbiosis in colitic mice. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-017-4767-8. ALJahdali N, Gadonna-Widehem P, Delayre-Orthez C, et al. Repeated oral exposure to N ε-carboxymethyllysine, a Maillard reaction product, alleviates gut microbiota dysbiosis in colitic mice. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-017-4767-8.
3.
go back to reference Delgado-Andrade C. Maillard reaction products: some considerations on their health effects. Clin Chem Lab Med. 2014;52:53–60.CrossRefPubMed Delgado-Andrade C. Maillard reaction products: some considerations on their health effects. Clin Chem Lab Med. 2014;52:53–60.CrossRefPubMed
Metadata
Title
Modulation of Gut Microbiota by Maillard Reaction Products in Intestinal Inflammation: Are We What We Eat?
Author
Adam Fabisiak
Publication date
01-12-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4796-3

Other articles of this Issue 12/2017

Digestive Diseases and Sciences 12/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.